303 related articles for article (PubMed ID: 23348428)
1. Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro.
Xu Y; Wu W; Wang L; Chintala M; Plump AS; Ogletree ML; Chen Z
Blood Coagul Fibrinolysis; 2013 Apr; 24(3):332-8. PubMed ID: 23348428
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation.
Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
Blood Coagul Fibrinolysis; 2007 Mar; 18(2):97-103. PubMed ID: 17287624
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the aPTT with alternative tests for monitoring direct thrombin inhibitors in patient samples.
Lind SE; Boyle ME; Fisher S; Ishimoto J; Trujillo TC; Kiser TH
Am J Clin Pathol; 2014 May; 141(5):665-74. PubMed ID: 24713737
[TBL] [Abstract][Full Text] [Related]
4. Distinct features of bivalent direct thrombin inhibitors, hirudin and bivalirudin, revealed by clot waveform analysis and enzyme kinetics in coagulation assays.
Wakui M; Fujimori Y; Nakamura S; Kondo Y; Kuroda Y; Oka S; Nakagawa T; Katagiri H; Murata M
J Clin Pathol; 2019 Dec; 72(12):817-824. PubMed ID: 31366633
[TBL] [Abstract][Full Text] [Related]
5. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate.
Dinkelaar J; Patiwael S; Harenberg J; Leyte A; Brinkman HJ
Clin Chem Lab Med; 2014 Nov; 52(11):1615-23. PubMed ID: 24902009
[TBL] [Abstract][Full Text] [Related]
6. Thrombin generation assay and viscoelastic coagulation monitors demonstrate differences in the mode of thrombin inhibition between unfractionated heparin and bivalirudin.
Tanaka KA; Szlam F; Sun HY; Taketomi T; Levy JH
Anesth Analg; 2007 Oct; 105(4):933-9, table of contents. PubMed ID: 17898368
[TBL] [Abstract][Full Text] [Related]
7. The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation.
Incampo F; Carrieri C; Semeraro N; Colucci M
Thromb Res; 2014 Nov; 134(5):1110-6. PubMed ID: 25193406
[TBL] [Abstract][Full Text] [Related]
8. Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography.
Solbeck S; Meyer MA; Johansson PI; Meyer AS; Cotton BA; Stensballe J; Schött U; Ostrowski SR
Int J Cardiol; 2014 Oct; 176(3):794-9. PubMed ID: 25156858
[TBL] [Abstract][Full Text] [Related]
9. [Direct inhibitors of thrombin, hirudin, bivalirudin, and dabigatran etexilate].
Meddahi S; Samama MM
J Mal Vasc; 2011 Feb; 36(1):24-32. PubMed ID: 21239127
[TBL] [Abstract][Full Text] [Related]
10. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin.
Bates SM; Weitz JI
Am J Cardiol; 1998 Oct; 82(8B):12P-18P. PubMed ID: 9809887
[TBL] [Abstract][Full Text] [Related]
11. Argatroban, bivalirudin, and lepirudin do not decrease clot propagation and strength as effectively as heparin-activated antithrombin in vitro.
Nielsen VG; Steenwyk BL; Gurley WQ; Pereira SJ; Lell WA; Kirklin JK
J Heart Lung Transplant; 2006 Jun; 25(6):653-63. PubMed ID: 16730571
[TBL] [Abstract][Full Text] [Related]
12. Only high levels of dabigatran attenuate catheter thrombosis in vitro and in rabbits.
Yau JW; Liao P; Fredenburgh JC; Roberts RS; Weitz JI
Thromb Haemost; 2014 Jul; 112(1):79-86. PubMed ID: 24573541
[TBL] [Abstract][Full Text] [Related]
13. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
Herrmann R; Thom J; Wood A; Phillips M; Muhammad S; Baker R
Thromb Haemost; 2014 May; 111(5):989-95. PubMed ID: 24352511
[TBL] [Abstract][Full Text] [Related]
14. Effective use of BCH-2763, a new potent injectable direct thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial thrombolysis model.
Deschênes I; Finkle CD; Winocour PD
Thromb Haemost; 1998 Jul; 80(1):186-91. PubMed ID: 9684808
[TBL] [Abstract][Full Text] [Related]
15. Thrombin-activated thrombelastography for evaluation of thrombin interaction with thrombin inhibitors.
Taketomi T; Szlam F; Vinten-Johansen J; Levy JH; Tanaka KA
Blood Coagul Fibrinolysis; 2007 Dec; 18(8):761-7. PubMed ID: 17982317
[TBL] [Abstract][Full Text] [Related]
16. Laboratory assays for the evaluation of recombinant hirudin.
Walenga JM; Hoppensteadt D; Koza M; Wallock M; Pifarre R; Fareed J
Haemostasis; 1991; 21 Suppl 1():49-63. PubMed ID: 1894197
[TBL] [Abstract][Full Text] [Related]
17. Activated protein C resistance testing for factor V Leiden.
Kadauke S; Khor B; Van Cott EM
Am J Hematol; 2014 Dec; 89(12):1147-50. PubMed ID: 25293789
[TBL] [Abstract][Full Text] [Related]
18. Measurement of dabigatran in standardly used clinical assays, whole blood viscoelastic coagulation, and thrombin generation assays.
van Ryn J; Grottke O; Spronk H
Clin Lab Med; 2014 Sep; 34(3):479-501. PubMed ID: 25168938
[TBL] [Abstract][Full Text] [Related]
19. In vitro studies using a global hemostasis assay to examine the anticoagulation effects in plasma by the direct thrombin inhibitors: dabigatran and argatroban.
He S; Wallèn H; Bark N; Blombäck M
J Thromb Thrombolysis; 2013 Feb; 35(2):131-9. PubMed ID: 22843196
[TBL] [Abstract][Full Text] [Related]
20. Translational success stories: development of direct thrombin inhibitors.
Coppens M; Eikelboom JW; Gustafsson D; Weitz JI; Hirsh J
Circ Res; 2012 Sep; 111(7):920-9. PubMed ID: 22982873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]